Hardan I - Search Results

1

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma.

Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Br J Haematol. 2003 Aug;122(3):457-64. doi: 10.1046/j.1365-2141.2003.04446.x. Br J Haematol. 2003. PMID: 12877674 Free article.

2

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced.

Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Biol Blood Marrow Transplant. 2004 Jul;10(7):484-93. doi: 10.1016/j.bbmt.2004.03.002. Biol Blood Marrow Transplant. 2004. PMID: 15205669 Free article.

3

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Exp Hematol. 2007 Apr;35(4):534-40. doi: 10.1016/j.exphem.2007.01.043. Exp Hematol. 2007. PMID: 17379063 Free article. Clinical Trial.

4

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.

Shimoni A, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Nagler A. Shimoni A, et al. Among authors: hardan i. Leuk Lymphoma. 2007 Dec;48(12):2352-9. doi: 10.1080/10428190701671051. Leuk Lymphoma. 2007. PMID: 18067010

5

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander AR, Kroger N, Nagler A. Shimoni A, et al. Among authors: hardan i. Cancer. 2010 Aug 1;116(15):3621-30. doi: 10.1002/cncr.25228. Cancer. 2010. PMID: 20564132 Free article.

6

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity.

Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Exp Hematol. 2003 May;31(5):428-34. doi: 10.1016/s0301-472x(03)00047-x. Exp Hematol. 2003. PMID: 12763142 Free article.

7

Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug.

Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, Ben-Bassat I. Kneller A, et al. Among authors: hardan i. Br J Haematol. 2000 Feb;108(2):391-3. doi: 10.1046/j.1365-2141.2000.01835.x. Br J Haematol. 2000. PMID: 10691870 Free article.

8

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Leukemia. 2003 Feb;17(2):290-7. doi: 10.1038/sj.leu.2402808. Leukemia. 2003. PMID: 12592325 Clinical Trial.

9

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.

Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A. Shimoni A, et al. Among authors: hardan i. Leukemia. 2005 Jan;19(1):7-12. doi: 10.1038/sj.leu.2403591. Leukemia. 2005. PMID: 15526016

10

Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.

Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: hardan i. Leukemia. 2006 Feb;20(2):322-8. doi: 10.1038/sj.leu.2404037. Leukemia. 2006. PMID: 16307018 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters